Life Sciences industry experts Michael D. Webb and Brian Cain bring extensive expertise in strategic pharmaceutical growth
DELAWARE, April 07, 2022 ─iQure Pharma Inc. (iQure), a US-based global biotech company, has appointed Michael D. Webb, president and CEO of CXL Ophthalmics, LLC, as its new chairperson and Brian E. Cain, president of InLine LLC and former executive director Commercial Insights & Analytics at Bristol-Myers Squibb/Celgene, as a new board member. They join board members Dr. Peter Schiemann, iQure co-founder and Pawel Zolnierczyk, iQure CEO and co-founder.
“It is a dynamic and exciting time for iQure,” said Pawel Zolnierczyk. “Our focus is on ensuring the board has the right experience, skills and talent and Michael and Brian are the perfect complements to usher in the next phase of iQure’s growth. Michael is exit driven with proven expertise in successfully working with companies similar to iQure. Brian has built his career focused on advancing the goals of large pharma, including Merck, Johnson & Johnson, and Genentech and contributes a profound understanding of the ‘buyer’ perspective.”
With more than 25 years of experience in healthcare and life sciences, Michael Webb has an innate understanding of creating a profitable exit for investors. He specializes in early-stage companies focused on targeted therapeutics and molecular diagnostics. Webb has founded multiple biotechnology companies, from seed round funding through venture financing and NASDAQ IPO filings. Webb began his career in healthcare and life sciences with Booz Allen Hamilton’s Chicago office and was also a senior vice president at CIBA-Geigy (now Novartis).
After earning bachelor’s degrees summa cum laude in biochemistry and economics from the University of Kansas, and an MA in International Relations from Sussex University in the UK, Webb completed his thesis on "Pharmaceuticals Policy and the World Health Organization." He holds an MBA from the Kellogg School of Management at Northwestern University, with a focus on healthcare management. He is also a former chair of the Massachusetts Biotechnology Council.
Brian Cain brings more than 25 years of strategically and cost-effectively growing key pharmaceutical brands through best-in-class market research, both domestic and global, business intelligence, customer insight mining, data strategy, forecasting, and commercial analytics. He has achieved targeted success for multi-billion-dollar products, excelling in dynamic, demanding environments while remaining pragmatic and focused.
For more information, please visit the iQure Pharma website.
About iQure Pharma
As a global biotech firm headquartered in the US, iQure Pharma is focused on the development of new therapeutics targeting neuropathic pain. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr. Anna Rzewuska at firstname.lastname@example.org.